MedTrace Logo

Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study

NCT00131274 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2005-10-05

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and efficacy of Gleevec (imatinib mesylate) in the treatment of idiopathic pulmonary fibrosis (IPF).

Conditions

Interventions

DRUG

Imatinib Mesylate (Gleevec)

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Daniels, Craig E., M.D.

    lead INDIV

Principal Investigators

  • Craig E Daniels, MD · Mayo Clinic

  • Joseph Lasky, MD · Tulane University

Study Design

Allocation
RANDOMIZED
Purpose
ECT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Completion
2007-08-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00131274 on ClinicalTrials.gov